Latest news with #Healthcare
Globe and Mail
an hour ago
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Veeva Systems (VEEV) and Elevance Health (ELV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Veeva Systems (VEEV – Research Report) and Elevance Health (ELV – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Sarepta Therapeutics (SRPT) Sarepta Therapeutics received a Hold rating and a $18.00 price target from Barclays analyst Gena Wang today. The company's shares closed last Monday at $13.32. According to Wang is a 3-star analyst with an average return of 2.8% and a 42.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, 4D Molecular Therapeutics, and BioMarin Pharmaceutical. ;'> The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $30.82 average price target, which is a 140.5% upside from current levels. In a report issued on July 18, Needham also downgraded the stock to Hold with a $50.00 price target. Veeva Systems (VEEV) In a report released today, Saket Kalia from Barclays maintained a Buy rating on Veeva Systems, with a price target of $300.00. The company's shares closed last Monday at $281.00. According to Kalia is a 5-star analyst with an average return of 16.5% and a 64.2% success rate. Kalia covers the Technology sector, focusing on stocks such as CCC Intelligent Solutions Holdings, Procore Technologies, and CrowdStrike Holdings. ;'> The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $295.52 average price target, which is a 4.5% upside from current levels. In a report issued on July 14, Wells Fargo also maintained a Buy rating on the stock with a $300.00 price target. Elevance Health (ELV) Barclays analyst Andrew Mok CFA maintained a Buy rating on Elevance Health today and set a price target of $327.00. The company's shares closed last Monday at $276.45. According to CFA is ranked 0 out of 5 stars with an average return of -8.4% and a 41.1% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'> Currently, the analyst consensus on Elevance Health is a Strong Buy with an average price target of $380.47, a 36.7% upside from current levels. In a report issued on July 8, Bernstein also maintained a Buy rating on the stock with a $585.00 price target.
Yahoo
5 hours ago
- Business
- Yahoo
H1 25 Results: Increased Profitability Despite Subdued Revenues
Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Baar, Switzerland--(Newsfile Corp. - July 23, 2025) - Ad hoc announcement pursuant to Art. 53 LR Half-Year 2025 Results To view an enhanced version of this graphic, please visit: Increased profitability despite subdued revenues HALF-YEAR 2025 HIGHLIGHTS Revenue at CHF 225.4m, -6.5% (- 4.6% organic FX adj.). Healthcare segment grew 7.5% (organic FX adj.) driven by Dental and Surgery. Consumer & Industrial segment declined 10.9 % organic FX adj. on low commercial activity and project delays in Beauty Adj. EBITDA margin at 19.9%, +80 bps YoY on higher Dental volume and continued gross profit margin improvements in Industry Segment gross profit margin up 390 bps to 47.9%, positively impacting EBIT as a percentage of revenues (+170 bps) Free Cash Flow at CHF 11.4m (+50.9% yoy); Operating Net Cash Flow (ONCF) at CHF 15.3m (-24.1% yoy) reflecting inventory build-up mainly in Dental to mitigate potential tariff impact Well on track with Growth and Efficiency program: CHF 15m savings impact secured, CHF 8.5m realized in first half 2025 and 70 efficiency initiatives initiated Acceleration of cost out initiatives and CHF 3m additional actions identified, specifically targeted at Beauty business unit Strengthened leadership team: new CHRO, CTO and Business Unit Head Drug Delivery Revised 2025 revenue guidance: decline similar to that seen in H1 2025 (FX adj.) Confirmed 2025 profitability guidance: adjusted EBITDA margin 18% to 19% Confirmed mid-term guidance: CAGR in revenue of above 4%, adj. EBITDA margin of above 20% CEO René Willi said: 'We are on track with our strategy to pivot to high growth/high margin healthcare businesses. We have significantly improved profitability, which on the one hand is driven by strong growth in our most profitable Healthcare businesses Dental and Surgery, and on the other hand, by the impact of our Growth and Efficiency program. Our group revenues have been impacted by lower Beauty sales, which were the result of lower commercial activity, project delays and a high comparable in H1 2024. We have accelerated additional cost out measures of CHF 3m targeted at our Beauty business unit to maintain our high profitability levels.' Revenue key figures To view an enhanced version of this graphic, please visit: GROUP REVIEW In the first half of 2025, medmix generated revenue of CHF 225.4 million, 6.5% lower year-on-year. Foreign exchange rate effects of -2.0% negatively impacted underlying organic volume growth during the period which stood at -4.6%. Compared to the second half of 2024, however, Group revenues declined by -7.1% on a reported basis and by -5.1% organically. Healthcare segment revenue grew strongly in the first half of 2025, with two of the three Healthcare business units delivering robust year-on-year organic growth well above market rates, Surgery 26.1% and Dental 10.1%. Adverse impacts from Drug Delivery offset some of this growth. Healthcare segment revenues increased by 6.2% on a reported basis and 7.5% organically, with the difference of -1.3% entirely due to foreign exchange effects. Dental business unit organic revenue grew 10.1% year-on-year due to successful growth outside the historically strong impression material sector, resulting in above market growth additionally supported by stronger market conditions. Sequential organic revenues were down slightly 0.3%, partly due to uncertainty generated by US tariffs timing. Drug Delivery business unit revenue declined by 4.9% organically as H1 2024 included some non-repeat project milestones due to close out of a customer project. Surgery business unit revenue saw a 26.1% organic increase due to a lower base in H1 2024. Our customer base is growing as we move our commercial and manufacturing HQ to Atlanta. A continuation of the positive growth trajectory of the Dental and Surgery business units' revenue is expected in the second-half, at a more normalized level. The second source impact in the Drug Delivery business unit will again partly offset this growth. Consumer & Industrial segment organic revenue declined by 10.9%, driven by continued weakness in the Beauty markets and overall low consumer confidence. Industry business unit revenue reached CHF 63.5 million in the first half of 2025, organically 1.3% lower versus the first half of 2024. Sequentially, the Industry business unit delivered robust organic growth of 5.6% as we continue to deliver our full portfolio from our plant in Valencia and expand our greenLine offering. Management remains cautious of the global economic landscape and its impact on the Industry business unit. Beauty business unit organic revenue declined year-on-year by 17.7% to CHF 73.8 million, due to project delays and lower commercial activity in our business. In comparison, H1 2024 saw Beauty's highest half-year revenue in five years, where it benefited from a high level of launch activity after the lifting of covid restrictions. We expect this slower activity to continue in the second half. We have seen an increase in customer projects activity in Q2 2025, which will provide revenue growth momentum in 2026. Additionally, medmix has accelerated decisive cost-out measures to adapt the cost base to business volume and protect profitability. Gross profit margin, segment gross profit Segment gross profit, which does not include shared cost and cost absorption, grew by 1.6% to CHF107.9 million, despite a decline in Group revenues, delivering a strong margin of 47.9%. Healthcare segment gross profit increased by CHF 3.9 million, a growth of 7.5% year-on-year, in line with the revenue growth. Resulting segment gross profit margin was a strong 62.7%. Dental and Surgery segments margin growth was partly offset by the profit pressure from the Drug Delivery business unit as it remains in ramp-up mode, with more projects than commercial product sales. Consumer & Industrial first-half segment gross profit decreased by 4.0% year-on-year, due to the impact of decrease in Beauty volumes. Importantly, the segment delivered a robust gross profit margin of 38.3%, an increase of 370bps year-on-year, driven by operational efficiencies from our Growth and Efficiency program, driving margin expansion across both Industry and Beauty business units. Adjusted EBITDA Group Adjusted EBITDA was CHF 44.9 million, a decrease of 2.5% year-on-year, with our Growth and Efficiency program limiting the impact on profitability resulting from lower revenues. While there was a decline in the absolute Adjusted EBITDA, Adjusted EBITDA margin was 19.9%, having grown sequentially for two consecutive halves, compared to 19.1% in H1 2024 and 19.2% in H2 2024. The group delivered a robust profitability improvement of 80bps year-on-year, offsetting the impact of lower volumes and additional investments made in our Growth and Efficiency program. The year-on-year and sequential improvement is primarily driven by the continuation of strong Dental volumes and operational efficiencies in Consumer and Industrial segment. EBIT increased year-on-year from CHF 12.9 million to CHF 15.7 million, EBIT as a percentage of revenues increased 170bps to 7.0%. Net income Net income increased by CHF 1.4 million to CHF 6.9 million (thereof CHF 6.8 million attributable to shareholders of medmix AG) from CHF 5.6 million (thereof CHF 5.2 million attributable to shareholders of medmix AG) in the prior period. Operating Net Cash Flow (ONCF) Operating Net Cash Flow for H1 2025 decreased to CHF 15.3 million compared to the same period a year ago (CHF 20.1 million) mainly due to inventory build-up in the Dental business unit while Free Cash Flow increased from CHF 7.6 million in H1 2024 to CHF 11.4 million in the first half of 2025, mainly due to lower CAPEX, which may however increase in the second half. GROWTH & EFFICIENCY PROGRAM Our Growth and Efficiency program launched in 2024 aims at enhancing growth by re-allocating resources to our strategic priorities and improving our performance by strategically reducing costs. With CHF 15 million savings impact secured and CHF 8.5 million realized in the first half of 2025, we are on track with our goal for H1 2025. We have implemented 70 efficiency initiatives, such as reducing headquarters and support functions or automating productions processes in our factories. We will also continue to invest in our sales organization and in R&D, which will ensure we remain at the forefront of innovation in both our segments. This program will not impact our ability to maintain our innovation pace and quality standards and will ultimately lead to an increase in our service levels. STRENGTHENED LEADERSHIP TEAM In the past half year, we have significantly strengthened our management team with seasoned leaders. Jasper Den Ouden joined medmix as of March this year as Chief Human Resources and Sustainability Officer. Jasper brings extensive international HR leadership experience. He most recently served as Chief Human Resources Officer at SR Technics Group in Zurich where he led HR for 2,200 employees and drove key initiatives in digital transformation, talent development, ESG and organizational change. We are also very happy to welcome Francisco Faoro and Oliver Haferbeck to our Executive Leadership Team. Oliver was appointed as the new Head of Drug Delivery Business Unit in June. He brings a wealth of international leadership experience in the healthcare and medical technology sectors. Most recently, he served as Head of Gerresheimer Advanced Technology and CEO of Sensile Medical AG, where he led innovation in advanced drug delivery systems. His tenure at Gerresheimer was marked by a strong focus on strategic growth, technological advancement, and operational excellence. Francisco Faoro joined medmix as Chief Technology Officer in May. Francisco brings extensive international leadership experience in technology and innovation. He held multiple senior leadership roles at Straumann Group, successfully preparing multiple implant innovations creating significant growth momentum. Prior to his tenure in the dental field, Francisco had several managerial positions in brand management and product development within the orthopedic and polymer processing industries. OUTLOOK Based on H1 2025 actuals and our outlook for the full year, we now expect a full year revenue decline similar to that seen in H1 2025 on an FX adjusted basis. Our 2025 guidance for profitability with an adjusted EBITDA margin of 18-19% remains unchanged, as does our mid-term guidance –over a three-year period– with a compound annual growth rate in revenues of above 4% and an adj. EBITDA margin above 20%. Key figures To view an enhanced version of this graphic, please visit: The medmix half-year report is available to download here. Half-year 2025 results presentation Webcast participation medmix management will present the half-year results 2025 as a webcast on July 23, 2025, at 08:30 CET. A webcast invitation was sent to medmix news subscribers early July. If you have not received it and wish to participate, please click here to pre-register by 08:00 CET latest to receive the link to the webcast and dedicated dial-in details. Webcast playback The playback of the webcast will be available shortly after the event under the same link. Inquiries Investor Relations: investorrelations@ Media Relations: communications@ Key dates in 2025/2026 February 26, 2026 Full-year results 2025 About medmix medmix is a global leader in high-precision delivery devices. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2,700 employees provide our customers with uncompromising quality, proximity, and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). Disclaimer This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Medical Coating Market worth $15,813.6 million by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., July 22, 2025 /PRNewswire/ -- The report " Medical Coatings Market by Coating Type (Active, Passive), By Material (Polymers, Metals), By Application (Medical Devices, Medical Implants, Medical Equipment & Tools), By Region – Global Forecast to 2030 ", medical coating market size is projected to reach 15,813.6 million by 2030 at a CAGR of 9.6% from USD 9,983.0 million in 2025. Factors contributing to the medical coating market include the rising prevalence of chronic diseases, increased demand for advanced medical devices, and a growing geriatric population. Other factors driving the adoption and innovation of medical coatings include improved infection control, the growth of minimally invasive procedures, and shorter trial studies related to regulatory requirements for biocompatibility. Browse in-depth TOC on "Medical Coating Market" 300 - Tables 50 - Figures 179 - Pages Download PDF Brochure: Metals will account for the second-largest share in the medical coating market by material during the forecast period, in terms of value. Metals are expected to hold the second-largest share of the medical coating market, by material, during the forecast period, in terms of value. Metals possess key attributes such as strength, combined with advantageous biocompatibility and durability, making them ideal for high-performance medical devices like orthopaedic implants and cardiovascular stents. Metals like silver and titanium have unique antimicrobial properties that help reduce infection risk inherently when used in implants and bearings. The growth in demand for metal coatings during this period is driven by advances in surface modification technologies and an increasing need for infection control within healthcare organizations. Medical implants will be the second-fastest-growing application in the medical coating market during the forecast period, in terms of value. During the forecast period, medical implants are the second fastest-growing application in the medical coating market in terms of value, mainly due to the rising prevalence of chronic diseases and the rapidly aging global population. Advances in biomaterials and coating technologies are also making implants safer and more durable with improved biocompatibility. In addition to these safety improvements, the increasing demand for orthopaedic, cardiovascular, and dental implants has driven growth across the market. Regulatory approvals and higher healthcare spending have likely supported this trend. Request Sample Pages: Europe accounts for the second-largest share in the medical coating market in terms of value. Europe holds the second-largest share by value in the medical coating market, after North America, thanks to the region's well-developed healthcare infrastructure and large medical device manufacturing base. The region is characterized by strict regulatory environments like the EU Medical Device Regulation (MDR) and a strong focus on infection prevention, control, and AM coatings. Countries such as Germany, France, and the United Kingdom are the main demand drivers for coated devices, especially those related to cardiovascular and orthopaedic applications. Additionally, rising healthcare expenditures and the rapid expansion of wearable technologies are boosting the industry's growth across Europe. Request Customization: Key Players Acquisitions and expansions serve as the main growth strategies used by leading companies in the market. The major global players in the medical coating industry include Hydromer (US), DSM-Firmenich (Netherlands), Surmodics (US), Biocoat Incorporated (US), AST Products Inc (US), Covalon Technologies (Canada), Freudenberg Medical (US), Harland Medical Systems, Inc (US), Merit Medical Systems (US), Applied Medical Coatings (US), PPG Industries, Inc. (US), and The Sherwin-Williams Company (US). Get access to the latest updates on Medical Coating Companies and Medical Coating Market Size Browse Adjacent Market: Coatings Adhesives Sealants & Elastomers Research Reports & Consulting Related Reports: Antimicrobial Coatings Market - Global Forecast to 2027 Thermal Spray Coatings Market - Global Forecast to 2028 Textile Coatings Market - Global Forecast to 2028 ETFE & ECTFE Coatings Market - Global Forecast to 2030 Industrial Coatings Market - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
a day ago
- Business
- Yahoo
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health and Community Health Systems
For Immediate Release Chicago, IL – July 22, 2025 – Today, Zacks Equity Research discusses HCA Healthcare, Inc. HCA, Tenet Healthcare Corp. THC, Universal Health Services, Inc. UHS and Community Health Systems, Inc. CYH. Industry: Hospitals Link: The Zacks Medical-Hospital industry faces mounting challenges, including rising labor costs, supply expenses, regulatory pressures and tightening budgets. Workforce burnout and cybersecurity risks continue to strain operations, while technological innovations offer long-term efficiency gains. Despite near-term headwinds, growing patient volumes may support gradual through mergers and acquisitions remains a key strategy, allowing hospitals to scale operations and increase market share in a fragmented landscape. Leading players HCA Healthcare, Inc., Tenet Healthcare Corp., Universal Health Services, Inc. and Community Health Systems, Inc. are demonstrating resilience by optimizing operations and expanding strategically to stay competitive in a complex and evolving healthcare environment. Industry Overview The Zacks Medical-Hospital industry comprises for-profit hospital companies that provide healthcare through different types of hospitals, such as acute care, rehabilitation and psychiatric. These hospital entities are engaged in internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, telehealth services, mental health care and diagnostic and emergency services. Revenues of these companies depend on inpatient occupancy levels, medical and ancillary services ordered by physicians and provided to patients, and the volume of outpatient procedures. These hospital companies receive payments for patient services from the government under the Medicare program, Medicaid, or similar programs, managed care plans (including plans offered through the American Health Benefit Exchanges), private insurers and directly from patients. 4 Key Trends to Watch in the Hospital Industry Elective procedures are on the rise, contributing to increased patient volumes across hospitals. U.S. Census Bureau projections show the 65+ population will grow from 17.3% in 2022 to 22.8% by 2050, amplifying demand for healthcare. Health spending is projected to hit $5.3 trillion by 2025, according to the Peterson-KFF Health System Tracker. However, technological advancements are likely to accelerate a shift from inpatient care to outpatient, ambulatory and home-based services, leaving many hospitals with underused beds and a heavy fixed-cost burden. Labor shortage, higher wages, supply chain disruptions and escalating benefit costs continue to squeeze hospital margins. In response, providers are embracing automation, refining staffing models, and renegotiating supplier contracts to manage expenses. Efforts to reduce reliance on contract labor are gaining traction, although burnout challenges persist. Meanwhile, cybersecurity threats are prompting higher insurance premiums, adding to financial strain. A new $50 billion federal fund aims to support rural and underserved hospitals, but several experts note it may fall short of covering broader funding gaps tied to Medicaid reimbursement changes. Hospitals are investing heavily in AI, automation, and real-time analytics to streamline care delivery and reduce operational inefficiencies. These tools are improving clinical outcomes, enhancing patient engagement, and supporting long-term cost savings. Simultaneously, telehealth, accelerated by the pandemic, has become a permanent and vital component of care, particularly for remote and underserved populations. M&A activity has rebounded strongly post-pandemic, as hospitals seek scale, efficiency, and financial resilience. With the industry still highly fragmented, consolidation is being driven by economic recovery, regulatory clarity and the need to adapt to changing care models. Strategic partnerships, technology-driven collaborations, and innovative delivery models are helping hospitals expand capacity and sharpen their competitive edge. Zacks Industry Rank Shows Bearish Outlook The group's Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, signals challenging near-term prospects. The Zacks Medical-Hospital industry, which is housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #181, which places it in the bottom 26% of nearly 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one. The industry's position in the bottom 50% of the Zacks-ranked industries is a result of a negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are becoming pessimistic about this group's earnings growth potential. As a matter of fact, the industry's earnings estimates for 2025 have gone down 0.2% since February-end. Despite the dull near-term prospects of the industry, we will present a few stocks that you may want to watch. But it's worth taking a look at the industry's shareholder returns and current valuation first. Industry Lags S&P 500 But Outperforms Sector The Zacks Medical-Hospital industry has underperformed the Zacks S&P 500 composite while outperforming the broader Medical sector in a year. The industry has gained 4.2% over this period, underperforming the S&P 500's appreciation of 13.1% and outperforming the broader sector's slide of 17.6%. Industry's Current Valuation On the basis of the trailing 12-month EV/EBITDA (Enterprise Value/ Earnings Before Interest Tax Depreciation and Amortization) ratio, which is commonly used for valuing hospital stocks, the industry trades at 7.84X compared with the S&P 500's 17.79X and the sector's 9.72X. Over the past five years, the industry has traded as high as 9.55X and as low as 6.45X, with a median of 8.03X. 4 Hospital Stocks Worth Your Attention HCA Healthcare: The company operates general and acute care hospitals and is well-positioned to benefit from rising patient volumes. Growth in inpatient surgeries, ER visits, and telemedicine is boosting performance and diversifying revenue. Strategic acquisitions and ongoing dividends and buybacks reflect its focus on expansion and shareholder returns. The Zacks Consensus Estimate for one of the biggest for-profit publicly traded hospitals' 2025 EPS indicates 15% year-over-year growth. HCA Healthcare beat earnings estimates in each of the past four quarters, the average surprise being 7.1%. The consensus mark for 2025 revenues signals a 5.7% increase from a year ago. Shares of the company have gained 20.3% over the year-to-date period. It currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Tenet Healthcare Corporation: The company operates a wide network of hospitals and facilities, with strong revenue growth driven by its Ambulatory Care and Hospital segments. The USPI unit remains a core growth engine, supported by strategic tuck-in acquisitions that continue to enhance its market position. The Zacks Consensus Estimate for Tenet Healthcare's 2025 and 2026 bottom line indicates 7.2% and 7% year-over-year growth. It beat earnings estimates in all the past four quarters, the average surprise being 26.4%. The consensus mark for 2025 and 2026 revenues is pegged at $20.9 billion and $21.9 billion, signaling an increase from $20.7 billion in 2024. Shares of the company have gained 38.7% over the year-to-date period. It currently has a Zacks Rank #3. Universal Health Services: The company operates acute care hospitals, outpatient centers, and behavioral health facilities, with specialties including autism, addiction, and military-related conditions. Growth is supported by rising patient days, network expansion, added licensed beds and strategic behavioral health joint ventures. The Zacks Consensus Estimate for Universal Health's 2025 and 2026 bottom line is pegged at $19.43 and $21.10 per share, respectively, up 17% and 8.6% year over year, respectively. It beat earnings estimates in three of the past four quarters and missed once, the average surprise being 13.8%. The consensus mark for 2025 and 2026 revenues indicates 8% and 5.2% year-over-year increases. Although shares of Universal Health have declined 5.9% over the year-to-date period, its improving operations are expected to support a future rebound. It currently sports a Zacks Rank #3. Community Health Systems: It operates a national network of acute care hospitals and outpatient centers, benefiting from higher occupancy rates and a growing telehealth focus. It is expanding through hospital acquisitions, enhancing specialty services, and improving efficiency. Strategic divestments of non-core assets aim to boost long-term profitability and cash flow, despite potential short-term impact. The Zacks Consensus Estimate for Community Health Systems' 2025 and 2026 bottom lines indicates 69.9% and 142.1% year-over-year improvements, respectively. The consensus mark for 2025 and 2026 revenues is pegged at $12.3 billion and $12.8 billion, respectively. Shares of Community Health Systems have gained 20% in the past week. It has a Zacks Rank #3 at present. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Community Health Systems, Inc. (CYH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Wall Street Journal
a day ago
- Health
- Wall Street Journal
Meet the Medicaid Double-Dippers
Democrats haven't taken a breath since the Republican budget bill passed, trying to scare Americans across the country that millions are about to lose Medicaid coverage. You won't read this elsewhere, but the government has now found that up to 2.8 million Americans are enrolled in two separate health plans underwritten by taxpayers. The Centers for Medicare and Medicaid Services (CMS) reported late last week that 1.2 million Americans last year were enrolled in Medicaid or the Children's Health Insurance Program in two or more states. The agency worked with software engineers to review enrollment data, and it found another 1.6 million enrolled in both Medicaid and an ObamaCare plan with taxpayer subsidies in 2024.
